Clinical trial · Interventional
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC
NCT02771405CI-TRIAL-00107828FRI-STCcompletedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study will recruit 150 patients with HCV related HCC ,after HCC treatment the patients will undergo treatment with different regimens of DAAs.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatitis C, Chronic | — | UNRESOLVED | — |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| daclatasvir | Drug | — | UNRESOLVED |
| Ledipasvir | Drug | — | UNRESOLVED |
| Ribavirin | Drug | — | UNRESOLVED |
| Simeprevir | Drug | — | UNRESOLVED |
| Sofosbuvir | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Sofosbuvir +Ribavirin
- description
- Sofosbuvir 400 mg/day +ribavirin for 24 weeks
- interventionNames
- Drug: Sofosbuvir
- Drug: Ribavirin
- type
- EXPERIMENTAL
- label
- Sofosbuvir+Simeprevir±Ribavirin
- description
- Sofosbuvir 400 mg/day +Simeprevir 150 mg/day ± ribavirin for 12 weeks
- interventionNames
- Drug: Sofosbuvir
- Drug: Ribavirin
- Drug: Simeprevir
- type
- EXPERIMENTAL
- label
- Sofosbuvir+Daclatasvir±Ribavirin
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18-70 years old * Confirmed HCV viremia by PCR * CHILD Pugh "A" or "B7,B8" * Confirmed HCC either by laboratory ,imaging or histopathological criteria * Underwent or candidate for curative intervention for HCC (BCLC stage 0 ,A) * Willing to be treated for HCV and signing informed consent Exclusion Criteria: * Patients below 18 or above 70 years old * patients with advanced liver condition "CHILD score ≥ B9" * Patients with advanced HCC status (BCLC≥ B) * Patients with combined HBV ,HIV infection
References
Publications (1)
- DERIVEDHassany M, Elsharkawy A, Maged A, Mehrez M, Asem N, Gomaa A, Mostafa Z, Abbas B, Soliman M, Esmat G. Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact. Eur J Gastroenterol Hepatol. 2018 Aug;30(8):876-881. doi: 10.1097/MEG.0000000000001152. PMID 29727383